RSCM
BCRX icon

Rock Springs Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Rock Springs Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221K Buy
22,124
+9,524
+76% +$86.1K 0.01% 103
2026
Q1 		$120K Buy
+12,600
New +$97.8K 0.01% 100
2025
Q2 		– Sell
-222,011
Closed -$1.67M – 94
2025
Q1 		$1.67M Sell
222,011
-2,455,985
-92% -$19.8M 0.1% 81
2024
Q4 		$20.1M Sell
2,677,996
-944,362
-26% -$7.17M 0.77% 45
2024
Q3 		$27.5M Buy
3,622,358
+3,100
+0.1% +$23.6K 0.9% 42
2024
Q2 		$22.4M Buy
3,619,258
+123,002
+4% +$679K 0.67% 49
2024
Q1 		$17.8M Buy
3,496,256
+225,875
+7% +$1.27M 0.45% 62
2023
Q4 		$19.6M Buy
3,270,381
+719,155
+28% +$4.17M 0.48% 60
2023
Q3 		$18.1M Buy
2,551,226
+54,033
+2% +$388K 0.48% 61
2023
Q2 		$17.6M Buy
2,497,193
+163,108
+7% +$1.31M 0.42% 61
2023
Q1 		$19.5M Buy
2,334,085
+443,348
+23% +$4.27M 0.46% 56
2022
Q4 		$21.7M Buy
1,890,737
+178,230
+10% +$2.22M 0.52% 54
2022
Q3 		$21.6M Buy
1,712,507
+251,416
+17% +$3.24M 0.56% 52
2022
Q2 		$15.5M Buy
+1,461,091
New +$15.1M 0.45% 60
2019
Q2 		– Sell
-700,000
Closed -$5.7M – 136
2019
Q1 		$5.7M Hold
700,000
– – 0.22% 105
2018
Q4 		$5.65M Hold
700,000
– – 0.27% 94
2018
Q3 		$5.34M Buy
700,000
+450,000
+180% +$3.02M 0.19% 116
2018
Q2 		$1.43M Sell
250,000
-675,000
-73% -$3.72M 0.06% 139
2018
Q1 		$4.41M Buy
925,000
+112,500
+14% +$578K 0.19% 124
2017
Q4 		$3.99M Buy
812,500
+362,500
+81% +$1.76M 0.18% 114
2017
Q3 		$2.36M Buy
+450,000
New +$2.3M 0.11% 128

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Rock Springs Capital Management's BCRX Position: Q2 2026 in Review

Rock Springs Capital Management increased its BioCryst Pharmaceuticals (BCRX) stake by 76% in Q2 2026, buying an estimated $86.1K and bringing the position to 22,124 shares worth $221K. The position accounts for 0.01% of the portfolio, ranked #103.

Rock Springs Capital Management first reported a position in BCRX in Q3 2017 and has held it in 21 quarters since. The position peaked at $27.5M in Q3 2024. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Rock Springs Capital Management held 22,124 shares of BioCryst Pharmaceuticals worth $221K as of Q2 2026.
  • Rock Springs Capital Management bought 9,524 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $86.1K.
  • BioCryst Pharmaceuticals made up 0.01% of Rock Springs Capital Management's portfolio in Q2 2026, its #103 holding.
  • Rock Springs Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2017 and has held it in 21 quarters since.
  • Rock Springs Capital Management's BioCryst Pharmaceuticals position peaked at $27.5M in Q3 2024.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.